Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Logo

Griffin Asset Management Inc decreased its stake in Regeneron Pharmaceuticals Inc (REGN) by 83.85% based on its latest 2018Q4 regulatory filing with the SEC. Griffin Asset Management Inc sold 3,763 shares as the company’s stock rose 19.30% with the market. The institutional investor held 725 shares of the health care company at the end of 2018Q4, valued at $271,000, down from 4,488 at the end of the previous reported quarter. Griffin Asset Management Inc who had been investing in Regeneron Pharmaceuticals Inc for a number of months, seems to be less bullish one the $41.67B market cap company. The stock decreased 2.68% or $10.54 during the last trading session, reaching $382.94. About 1.25M shares traded or 82.54% up from the average. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has risen 34.82% since April 15, 2018 and is uptrending. It has outperformed by 30.45% the S&P500. Some Historical REGN News: 10/03/2018 – REGENERON, SANOFI SAY PRALUENT PRICING OFFER TO BE TIED TO INDEPENDENT ICER REVIEW OF NEW RISK REDUCTION DATA; 11/05/2018 – Bayer: Eylea Treats Visual Impairment From Macular Degeneration; 21/03/2018 – The PCSK9 of NASH? Regeneron and Alnylam join forces to tackle a promising target for severe liver diseases $REGN $ALNY; 01/05/2018 – Regeneron and Sanofi to Lower Net Price of Praluent® (alirocumab) Injection in Exchange for Straightforward, More Affordable P; 01/05/2018 – REGENERON: EXPRESS SCRIPTS SELECTS PRALUENT EXCLUSIVE THERAPY; 23/04/2018 – Regeneron Announces Upcoming Investor Conference Presentations; 10/03/2018 – REG-Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need; 16/05/2018 – Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO; 29/03/2018 – Regeneron/Sanofi’s Dupixent (dupilumab) Drug Analysis 2018 – ResearchAndMarkets.com; 31/05/2018 – CLEARSIDE BIOMEDICAL INC – SUPRACHOROIDAL CLS-TA USED TOGETHER WITH INTRAVITREAL EYLEA WAS GENERALLY WELL TOLERATED

Raging Capital Management Llc increased its stake in Cvr Partners Lp (UAN) by 5.04% based on its latest 2018Q4 regulatory filing with the SEC. Raging Capital Management Llc bought 256,786 shares as the company’s stock rose 4.80% with the market. The hedge fund held 5.35 million shares of the basic industries company at the end of 2018Q4, valued at $18.21M, up from 5.10M at the end of the previous reported quarter. Raging Capital Management Llc who had been investing in Cvr Partners Lp for a number of months, seems to be bullish on the $433.87 million market cap company. The stock increased 2.13% or $0.08 during the last trading session, reaching $3.83. About 85,291 shares traded. CVR Partners, LP (NYSE:UAN) has risen 11.33% since April 15, 2018 and is uptrending. It has outperformed by 6.96% the S&P500. Some Historical UAN News: 13/04/2018 – LIGAND PHARMACEUTICALS SAYS ON APRIL 2, CO SENT COMPUTERSHARE, AS RIGHTS AGENT UNDER GLUCAGON CVR AGREEMENT – SEC FILING; 05/04/2018 – CONVIVIALITY CVR APPOINTMENT OF ADMINISTRATORS/NOMAD; 29/05/2018 – DGAP-NEWS: CVR MEDICAL AND CVR GLOBAL REACH STRATEGIC AGREEMENT; 11/04/2018 – ClinicalTrial US: Prediction of WMH in Migraine Using a BOLD-CVR Map; 28/03/2018 – CONVIVIALITY CVR UPDATE ON FUNDRAISING; 26/04/2018 – CVR Partners 1Q Loss/Shr 17c; 04/04/2018 – CONVIVIALITY CVR PROPOSED SALE OF; 26/04/2018 – CVR Partners Will Not Pay Cash Distribution for 1Q; 29/05/2018 – CVR MEDICAL, CVR GLOBAL REACH STRATEGIC PACT; 30/05/2018 – S&PGR Affms CVR Partners ‘B+’ Rtgs; Otlk Rvd To Neg

Investors sentiment increased to 1.83 in Q4 2018. Its up 0.39, from 1.44 in 2018Q3. It is positive, as 8 investors sold UAN shares while 4 reduced holdings. 9 funds opened positions while 13 raised stakes. 38.41 million shares or 5.95% more from 36.25 million shares in 2018Q3 were reported. Hartford Financial Management stated it has 0.01% of its portfolio in CVR Partners, LP (NYSE:UAN). Us Bancorp De holds 0% of its portfolio in CVR Partners, LP (NYSE:UAN) for 1,040 shares. Savings Bank Of America De, North Carolina-based fund reported 256,162 shares. Regions Corporation has 8,120 shares for 0% of their portfolio. 396,908 were accumulated by Wells Fargo And Com Mn. Virtu Fin Lc invested 0% of its portfolio in CVR Partners, LP (NYSE:UAN). Barclays Plc accumulated 0.01% or 5.57M shares. Hsbc Public Limited holds 0% or 49,060 shares. Mirae Asset Invs Com holds 0% or 31,806 shares. Forbes J M Com Ltd Liability Partnership invested 0.01% of its portfolio in CVR Partners, LP (NYSE:UAN). California Pub Employees Retirement Systems invested in 183,499 shares. Indexiq Advsrs Limited Liability Corporation has invested 0% in CVR Partners, LP (NYSE:UAN). 1.87M are held by Glendon Management Limited Partnership. Next Fincl Grp Incorporated has invested 0% in CVR Partners, LP (NYSE:UAN). Bollard Grp Inc Llc has invested 0% in CVR Partners, LP (NYSE:UAN).

Raging Capital Management Llc, which manages about $631.31 million and $695.24M US Long portfolio, decreased its stake in Xilinx Inc (NASDAQ:XLNX) by 122,120 shares to 155,080 shares, valued at $13.21 million in 2018Q4, according to the filing. It also reduced its holding in Harmonic Inc (NASDAQ:HLIT) by 378,548 shares in the quarter, leaving it with 6.03M shares, and cut its stake in Assured Guaranty Ltd (NYSE:AGO).


More notable recent CVR Partners, LP (NYSE:UAN) news were published by: Nasdaq.com which released: “Mid-Morning Market Update: Markets Open Higher; DSW Beats Q3 Expectations – Nasdaq” on December 11, 2018, also 247Wallst.com with their article: “Goldman Sachs Has 5 More Stocks Under $10 to Buy With Huge Upside Potential – 24/7 Wall St.” published on December 01, 2018, Globenewswire.com published: “CVR Partners to Release Fourth Quarter 2018 Earnings – GlobeNewswire” on February 07, 2019. More interesting news about CVR Partners, LP (NYSE:UAN) were released by: Globenewswire.com and their article: “CVR Partners Reports 2018 Fourth Quarter and Full-Year Results And Announces Cash Distribution of 12 Cents – GlobeNewswire” published on February 20, 2019 as well as Bizjournals.com‘s news article titled: “Sugar Land-based refiner CVR Energy names new general counsel amid corporate consolidation – Houston Business Journal” with publication date: July 02, 2018.

Analysts await Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to report earnings on May, 2. They expect $5.24 EPS, up 31.66% or $1.26 from last year’s $3.98 per share. REGN’s profit will be $570.14M for 18.27 P/E if the $5.24 EPS becomes a reality. After $5.92 actual EPS reported by Regeneron Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -11.49% negative EPS growth.

More notable recent Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) news were published by: Nasdaq.com which released: “Notable Thursday Option Activity: BA, REGN, EA – Nasdaq” on March 21, 2019, also Globenewswire.com with their article: “Recent Analysis Shows Mastercard, Halliburton, Keysight Technologies, Eli Lilly, Wabash National, and Regeneron Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth – GlobeNewswire” published on March 25, 2019, Seekingalpha.com published: “Long-Term Outlook For Regeneron Pharmaceuticals – Seeking Alpha” on December 18, 2018. More interesting news about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) were released by: Bizjournals.com and their article: “Peninsula biotech lines up chance to crack the peanut allergy nut – San Francisco Business Times” published on March 25, 2019 as well as Nasdaq.com‘s news article titled: “REGN Makes Notable Cross Below Critical Moving Average – Nasdaq” with publication date: April 12, 2019.

Investors sentiment decreased to 1.13 in 2018 Q4. Its down 0.01, from 1.14 in 2018Q3. It fall, as 52 investors sold REGN shares while 165 reduced holdings. 72 funds opened positions while 174 raised stakes. 77.33 million shares or 9.82% more from 70.41 million shares in 2018Q3 were reported. Delaware-based Riverhead Cap Ltd Liability has invested 0.04% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Wunderlich Cap Managemnt invested in 4,568 shares or 1.31% of the stock. Wells Fargo Mn holds 260,777 shares. Commonwealth Of Pennsylvania Pub School Empls Retrmt Systems holds 0.03% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 4,234 shares. Temasek (Private) reported 126,351 shares. Tci Wealth reported 0% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Hartford Invest Mgmt reported 8,529 shares. Deutsche Financial Bank Ag stated it has 490,086 shares or 0.13% of all its holdings. Landscape Capital Mngmt Ltd Llc accumulated 0.06% or 2,061 shares. Veritable LP stated it has 0.02% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Gam Ag, Switzerland-based fund reported 1,270 shares. Moreover, Kistler has 0.01% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 39 shares. Meiji Yasuda Asset Mngmt Comm owns 0.1% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 2,864 shares. Central Natl Bank Trust reported 0.98% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Los Angeles Cap And Equity holds 74,752 shares or 0.17% of its portfolio.

Since December 12, 2018, it had 0 insider purchases, and 4 selling transactions for $55.44 million activity. Fenimore Christopher R. also sold $663,381 worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares. $2,294 worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was sold by VAGELOS P ROY on Wednesday, December 12. 131,115 shares were sold by Sanofi, worth $54.04M.

Griffin Asset Management Inc, which manages about $394.93M and $592.54M US Long portfolio, upped its stake in Abbvie Inc. (NYSE:ABBV) by 5,816 shares to 129,723 shares, valued at $11.96M in 2018Q4, according to the filing. It also increased its holding in Medtronic Inc (NYSE:MDT) by 5,900 shares in the quarter, for a total of 37,019 shares, and has risen its stake in Universal Display Corp (NASDAQ:OLED).

CVR Partners, LP (NYSE:UAN) Institutional Positions Chart




Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *